1. α-ketoglutarate suppresses immediate early gene expression in cancer cells.
- Author
-
Joo, Sungmin, Baek, Seungwoo, Kang, Jaehyeon, Seo, Dong Soo, Kwon, Taeg Kyu, and Jang, Younghoon
- Subjects
- *
GENE expression , *CANCER genes , *KREBS cycle , *CELL death , *CANCER cells , *DRUG metabolism - Abstract
Cancer cells exhibit increased glutamine consumption compared to normal cells, supporting cell survival and proliferation. Glutamine is converted to α-ketoglutarate (αKG), which then enters the tricarboxylic acid cycle to generate ATP. Recently, therapeutic modulation of glutamine metabolism has become an attractive metabolic anti-cancer strategy. However, how synergistic combination therapy is required to overcome glutamine metabolism drug resistance remains elusive. To address this issue, we first investigated the role of αKG in regulating gene expression in several cancer cell lines. Using RNA-seq analysis and histone modification screening, we demonstrated that αKG reduced the expression of the immediate early gene (IEG) in cancer cells in an H3K27 acetylation-dependent manner. Conversely, glutaminase (GLS) inhibitors induce IEG expression in cancer cells. Furthermore, we showed that siRNA knockdown of orphan nuclear receptor subfamily 4 group A member 1 (NR4A1) induces IEG expression. Notably, the NR4A1 agonist cytosporone B sensitizes GLS inhibitor resistance to cancer cell death. Together, these findings indicate that therapeutic targeting of IEG dysregulation by αKG can be a potentially effective anti-cancer therapeutic strategy for glutamine metabolism inhibitors. [Display omitted] • αKG reduces IEG expression in cancer cells in a H3K27 acetylation-dependent manner. • GLS inhibitors induce IEG expression in cancer cells. • NR4A1 agonist sensitizes GLS inhibitor resistance to cancer cell death. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF